A5085077539- Polyomavirus and related diseases
- Parvovirus B19 Infection Studies
- Hematological disorders and diagnostics
- Cytomegalovirus and herpesvirus research
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrest and Resuscitation
- Mechanical Circulatory Support Devices
- Prosthetics and Rehabilitation Robotics
- Transplantation: Methods and Outcomes
- Infectious Diseases and Tuberculosis
- Organ and Tissue Transplantation Research
- Virus-based gene therapy research
- Medical Imaging and Pathology Studies
- Anatomy and Medical Technology
- Bone and Joint Diseases
- Thermal Regulation in Medicine
Brigham and Women's Hospital
2014-2020
Harvard University
2020
Methodist Hospital
2016-2018
Unfractionated heparin is the preferred anticoagulant in extracorporeal membrane oxygenation (ECMO) patients. However, there a lack of consensus on its titration and monitoring. The objective this study was to describe efficacy safety pharmacy managed protocol utilizing activated partial thromboplastin time (aPTT) comparison our standard physician-managed clotting (ACT)-based anticoagulation ECMO patients.Patients administered drip while were included study. primary endpoints incidence...
Hypothermic ex-situ machine perfusion (MP) has been shown to be a promising alternative static cold storage (SCS) for preservation of solid organs transplantation and vascularized composite allotransplantation. Perfusion with blood-based solutions in austere environments is problematic due their need appropriate short shelf life, making it impractical military emergency use. Acellular effective, but the ideal perfusate solution MP amputated limbs yet determined. The purpose this study...
Alemtuzumab, a monoclonal antibody targeting CD52 that causes lymphocyte apoptosis, is form of advanced immunosuppression currently used as therapy for refractory acute cellular rejection and chronic lung allograft dysfunction in transplant recipients.Side effects alemtuzumab include bone marrow suppression, infection malignancy. Whether can be safely recipients have an increased propensity suppression due to telomeropathies unknown.In retrospective case series, we report outcomes associated...
Abstract Background Up to 20% of renal transplant recipients ( RTR ) will develop human BK polyomavirus BKP yV) viremia. yV viremia is a pre‐requisite polyomavirus‐associated nephropathy (Py VAN ). Risk infections increases with immunosuppression. Currently, the only effective therapy against Py reductions in immunosuppression, but this may increase risk rejection. In vitro data have shown that pravastatin dramatically decreased caveolin‐1 expression proximal tubular epithelial cells HRPTEC...
Abstract Background Fever occurs frequently early after pancreas transplant, however, the exact cause is often undetermined. Limited data are available on recipients experiencing unexplained, noninfectious fever. This study aims to characterize unexplained fever ( UF ) in and its effect patient graft outcomes. Methods We performed a retrospective cohort of among consecutive or simultaneous pancreas‐kidney transplant from 1 January 2011 31 August 2015. Classification was based absence...
Introduction: It has been estimated that after renal transplantation up to 20% of patients will develop BK viremia. Literature suggests viremia appears be a pre-requisite for the development polyomavirus-associated nephropathy (PyVAN). reported sustained, high viral loads may increase risk PyVAN. However, impact recurrent in patient who had previously cleared virus not evaluated. Hereinto, we evaluate on transplant-related outcomes transplant recipients Methods: A retrospective study was...
Introduction: It has been estimated that after renal transplantation up to 20% of patients will develop BK viremia. Literature suggests viremia appears be a pre-requisite for the development polyomavirus-associated nephropathy (PyVAN). There is correlation between an increased incidence virus infections in transplant recipients and degree immunosuppression. Currently, only efficient therapy against PyVAN reduction immunosuppression, but this may increase inherent risk rejection. In vitro...